Fig. 2.
Flow diagram of the process to identify effective medications supported by high- or moderate-quality evidence. aStatistically significant at the p < 0.05 level. bEstimates were for subgroup estimates that did not meet our criteria for quality assessment. cSubgroup or sensitivity analysis as defined by authors. dPre-specified in the methods section of the review article. eUnique at the level of pharmacological subgroup in the World Health Organization’s Anatomical Therapeutic Chemical classification system. fUnique at the three-character coding level using the World Health Organization’s 10th revision of the International Statistical Classification of Diseases and Related Health Problems